Fulvestrant SDZ IM Injection

Many breast cancers have estrogen receptors (ER) and the growth of these tumors can be stimulated by estrogen. Fulvestrant is an estrogen receptor antagonist that binds to the estrogen receptor in a competitive manner with affinity comparable to that of estradiol and downregulates the ER protein in human breast cancer cells.

In vitro studies demonstrated that fulvestrant is a reversible inhibitor of the growth of tamoxifen-resistant, as well as estrogen-sensitive human breast cancer (MCF-7) cell lines. In in vivo tumor studies, fulvestrant delayed the establishment of tumors from xenografts of human breast cancer MCF-7 cells in nude mice. Fulvestrant inhibited the growth of established MCF-7 xenografts and of tamoxifen-resistant breast tumor xenografts.

Fulvestrant showed no agonist-type effects in in vivo uterotrophic assays in immature or ovariectomized mice and rats. In in vivo studies in immature rats and ovariectomized monkeys, fulvestrant blocked the uterotrophic action of estradiol. In postmenopausal women, the absence of changes in plasma concentrations of FSH and LH in response to fulvestrant treatment (250 mg monthly) suggests no peripheral steroidal effects.

Fulvestrant 500 mg should be administered intramuscularly into the buttocks (gluteal area) slowly (1-2 minutes per injection) as two 5 mL injections, one in each buttock, on Days 1, 15, 29, and once monthly thereafter. 

A dose of 250 mg is recommended in patients with moderate hepatic impairment to be administered intramuscularly into the buttock (gluteal area) slowly (1-2 minutes) as one 5 mL injection on Days 1, 15, 29, and once monthly thereafter.

Pediatric Use: Safety and effectiveness in pediatric patients have not been established.

There are no known drug-drug interactions. Although Fulvestrant SDZ SDZ is metabolized by CYP 3A4 in vitro, drug interaction studies with ketoconazole or rifampin did not alter Fulvestrant SDZ SDZ pharmacokinetics. Dose adjustment is not needed in patients co-prescribed CYP 3A4 inhibitors or inducers.

The most common adverse reactions occurring in ≥5% of patients receiving Fulvestrant SDZ SDZ 500 mg were: injection site pain, nausea, bone pain, arthralgia, headache, back pain, fatigue, pain in extremity, hot flash, vomiting, anorexia, asthenia, musculoskeletal pain, cough, dyspnea, and constipation.

Increased hepatic enzymes (ALT, AST, ALP) occurred in >15% of Fulvestrant SDZ SDZ patients and were not dose-dependent.

There are no available data in pregnant women to inform the drug-associated risk. There is no information regarding the presence of fulvestrant in human milk, nor of its effects on milk production or breastfed infant. 

Risk of Bleeding: Use with caution in patients with bleeding diatheses, thrombocytopenia, or anticoagulant use.

Increased Exposure in Patients with Hepatic Impairment: Use a 250 mg dose for patients with moderate hepatic impairment.

Injection Site Reaction: Use caution while administering Fulvestrant SDZ SDZ at the dorsogluteal injection site due to the proximity of the underlying sciatic nerve.

Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception.

Immunoassay Measurement of Serum Estradiol: Fulvestrant SDZ SDZ can interfere with estradiol measurement by immunoassay, resulting in falsely elevated estradiol levels.

Human experience of overdose with Fulvestrant SDZ SDZ is limited. There are isolated reports of overdose with Fulvestrant SDZ SDZ in humans. No adverse reactions were seen in healthy male and female volunteers who received intravenous Fulvestrant SDZ SDZ, which resulted in peak plasma concentrations at the end of the infusion, that were approximately 10 to 15 times those seen after intramuscular injection. The potential toxicity of Fulvestrant SDZ SDZ at these or higher concentrations in cancer patients who may have additional comorbidities is unknown. There is no specific treatment in the event of Fulvestrant SDZ SDZ overdose, and symptoms of overdose are not established. In the event of an overdose, healthcare practitioners should follow general supportive measures and should treat symptomatically.

Refrigerate 2°-8°C. To protect from light, store in the original carton until the time of use.